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It is well-established that malignant tumour invasion and metas-
tasis involve a cascade of linked sequential events (Liotta et al,
1983). In addition to the loss of cell growth control, an imbalanced
regulation of motility and proteolysis appears to be required for
invasion and metastasis. An essential step is the breakdown and
removal of extracellular matrix (ECM), mediated by several
proteases, the most important of which appear to be matrix metal-
loproteinases (MMP) and serine proteases (Liotta et al, 1980;
Danø et al, 1985; Edmonard and Grimaud, 1990). In fact, the
MMPs, 72 kDa and 92 kDa type IV collagenases (MMP-2 and
MMP-9 respectively), and the serine proteinase, urokinase-type
plasminogen activator (uPA), are mainly involved in tumour inva-
sion and metastasis (Blasi et al, 1986). On the other hand, plas-
minogen activator inhibitors (PAIs) and tissue inhibitors of
metalloproteinases (TIMPs) are naturally occurring protease
inhibitors (Andreasen et al, 1990; Liotta et al, 1991). The activity
ratios uPA/PAI, MMP9/TIMP1 and MMP2/TIMP2 are maintained
at a delicate balance under physiological conditions, but a tempo-
rary shift towards proteolysis is needed during tissue remodelling
and normal angiogenesis (Montesano, 1992).
An imbalance of positive and negative regulation appears to
be required for tumour angiogenesis, invasion and metastasis
(Liotta et al, 1991). Pathological angiogenesis induced by solid
tumours and required for their progression seems to be the result
of an imbalance between angiogenic factors and inhibitors
(Folkman and Shing, 1992; Folkman, 1995). It is postulated that
a modulation of the protease/inhibitor or angiogenic factor/
anti-angiogenic factor ratios leading to a radical decrease of any
of them (that is, a shift towards inhibition of proteolytic and/or
angiogenic activities) could lead to tumour regression and/or
micrometastasis dormancy (Holmgren et al, 1995). Recently, a
dietary-derived tyrosine kinase inhibitor and an endogenous
oestrogen metabolite, namely, genistein and 2-methoxyestradiol,
have been isolated from human urine and they have been shown
to inhibit angiogenesis (Schweigerer et al, 1992; Fotsis et al,
1993, 1994). Since breakdown and removal of ECM is a feature
shared by both angiogenesis and tumour invasion, it seemed
interesting to us to study whether these compounds, genistein and
2-methoxyestradiol, can modulate the proteolytic balances in
tumour cells. It was also interesting to study the relationships
between their potential modulatory capacity and their ability to
inhibit tumour cell growth. The present work summarizes the data
we have obtained in a comprehensive comparative study of the
effects of genistein and 2-methoxyestradiol on both cell prolifera-
tion and proteolytic balance in different human tumour cell lines.
MATERIAL AND METHODS
Materials
Culture media, serum and antibiotics were from Gibco (Gent,
Belgium) and BioWhittaker (USA) and Trasylol from Bayer
(Leverkusen, Germany). All other reagents were molecular
biology grade and supplied by Sigma (St Louis, MO, USA),
Bio-Rad (Hercules, CA, USA), Merck (Darmstad, Germany) and
Fluka (Buchs, Switzerland).
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All the cell lines mentioned below were cultured in 10 cm-
diameter cell culture plates at 37°C under 5% carbon dioxide, in
media containing streptomycin, penicillin and amphoterycin, and
supplemented with 10% fetal calf serum (with the exception of
WAC2 cells). Among the cells used in the present work, there
were human breast cancer (MCF-7, MDA-MB231, ZR-75-1,
BT-474, Hs578T and SKBR-3), neuroblastoma (LAN-5 and
WAC2), colon adenocarcinoma (HT-29), fibrosarcoma (HT-1080),
osteosarcoma (U2-OS) and rhabdomyosarcoma (A-204) cell lines.
WAC2 cells are stable transfected neuroblastoma cells derived
from the SH-EP line and containing a plasmid with the coding
sequence for the N-myc oncogene (Schweigerer et al, 1990); these
cells were grown in RPMI-1640 medium supplemented with 10%
calf serum and selected by the addition of geneticin (200 mg ml–1)
to the culture medium. BT-474, MDA-MB231, SKBR-3, ZR-75-1
and LAN-5 cells were grown in RPMI-1640 medium; A-204,
HT-1080 and Hs578T cells were grown in Dulbecco’s modified
Eagle medium (DMEM) (with the addition of insulin, 10 mg ml–1,
in the case of Hs578T cells); MCF-7 and HT-29 cells were grown
in DMEM–F12 medium; and U2-OS were grown in McCoy’s 5a
medium. Cell counts were carried out with a Coulter counter.
Conditioned media
To prepare conditioned media, cells were grown in 6-well plates.
When the cells were subconfluent, medium was aspirated, cells
were washed twice with phosphate-buffered saline (PBS) and each
well received 1 ml of culture medium without serum and with
200 KIU of Trasylol ml–1. Additionally, some wells received
genistein (50 mM) or 2-methoxyestradiol (10 mM). After 24 h of
incubation, conditioned media were collected and centrifuged at
1000 g for 20 min. Afterwards, the supernatants were collected
and used for zymography. The cells were washed twice with PBS
and photographed under phase contrast in a Nikon Diaphot-TMD
microscope. Duplicates were used to determine cell number.
Assays of toxicity
To determine the IC50 values of the agents tested, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye reduction assay was carried out as previously described
(Mossmann, 1983).
Zymographies for PA and PAI activities
Aliquots of conditioned media normalized for equal cell numbers
were subjected to sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) at 4°C under non-reducing condi-
tions, with 3% stacking gel and 10% resolving gel. Gels were
washed for 10 min twice with 2.5% Triton X-100 and twice with
PBS and layed over a substrate gel prepared with agar (0.8%),
plasminogen (40 mg ml–1) and skimmed milk (1.5% in PBS). Gels
were incubated under a moist atmosphere overnight at 4°C and
afterwards they were incubated at 37°C. After 4–8 h, bands of
proteolysis due to uPA activity were photographed under dark
field. After an additional day of incubation at room temperature,
the only white areas under dark field illumination (due to the pres-
ence of skimmed milk protein) were those corresponding to bands
protected against proteolytic activity, and they represent the bands
of PAI activity.
Direct and reverse gelatinolytic assays
The gelatinolytic activity of MMP-2 and MMP-9 delivered to the
conditioned media by the different tumour cells was detected in
gelatinograms as follows. Samples were subjected to non-reducing
SDS-PAGE as above but with gelatin (1 mg ml–1) added to the
10% resolving gel. After electrophoresis, gels were washed twice
with 50 mM Tris-HCl, pH 7.4, supplemented with 2% Triton
X-100, and twice with 50 mM Tris-HCl, pH 7.4. Each wash was
for 10 min and with continuous shaking. After the washes, the gels
were incubated at 37°C for 24 h immersed in a substrate buffer
(50 mM Tris-HCl, pH 7.4, supplemented with 1% Triton X-100,
5m M calcium chloride and 0.02% Na3N). Afterwards, the gels
were stained with Commassie blue R-250 and the bands of
gelatinase activity could be detected as non-stained bands in a
dark, stained background. To detect stromelysin, caseinograms
were carried out as described for gelatinograms, using a- or
b-casein at 1 mg ml–1 instead of gelatin.
To detect TIMP activities some modifications were required.
Media conditioned by PMA-treated HT-1080 cells were treated
with 2% SDS at room temperature for 30 min and added (20% v/v)
to the 12% resolving gel. Prior to the addition of the stacking gel,
an electrophoretic run was carried out until the moment in which
the front line containing the phenol red of the conditioned medium
reached the end of the gel. From here on the procedure was the
same as in the case of direct gelatinolytic assay. In this case, the
bands of TIMP activity could be detected as dark bands over a
clearer background.
Quantitative analysis of bands of activity
Bands of activity in the zymograms and gelatinograms were
quantified with an lbas image analyser.
RESULTS
Effects of genistein and 2-methoxyestradiol on tumour
cell proliferation
The effects of both compounds, genistein and 2-methoxyestradiol,
have been tested on a wide range of human tumour cell lines,
including breast cancer (BT-474, Hs578T, MCF-7, MDA-MB231,
ZR-75-1), colon adenocarcinoma (HT-29), neuroblastoma
(LAN-5, WAC2), osteosarcoma (U2-OS), rhabdomyosarcoma
(A-204) and fibrosarcoma (HT-1080) cell lines.
First of all, it was necessary to access the growth rate curves
obtained for the different cell lines in the culture conditions of our
lab. As expected, the profiles of all the curves were similar, though
the proliferation rates varied in a wide range (Figure 1). Among
breast cancer cell lines, the most proliferant one was MDA-
MB231, a hormone-insensitive cell line. MCF-7 cells had a
medium proliferation rate, and all the other breast cancer cell lines
showed the lowest proliferation rates. Both rhabdomyosarcoma
A-204 and fibrosarcoma HT-1080 cells showed complete growth
curves in the period tested with regression of the populations
from the fourth day; their proliferation rates were medium.
Osteosarcoma U2-OS cells also had a medium proliferation rate
but they grew continuously from the second to the sixth day
showing no sign of regression. Finally, the highest proliferation
rates were those of colon adenocarcinoma HT-29 and neuro-
blastoma (WAC2, LAN-5) cell lines, with decay of the growth
from the fourth day on, only for LAN-5 cells.
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tional viability assays with MTT (Table 1). There were no clear
correlations among IC50 values and the proliferation rates or the
cell types. Significantly, among breast cancer cell lines, the
hormone-independent MDA-MB231 cell line was much more
sensitive to toxicity by both compounds than the other, hormone-
dependent breast cancer cell lines tested. In all the cases, IC50
values for 2-methoxyestradiol were much lower than those for
genistein.
Figures 2 and 3 show the typical morphological changes
induced by both treatments on some of the cell lines tested.
Genistein-treated cells emitted projections, suggesting that they
had acquired a differentiated phenotype. Some cells resembled
apoptotic cells with blebbing of the cytoplasm. On the other hand,
2-methoxyestradiol-treated cells losed their shape and acquired a
more rounded aspect.
Screening of proteases and their inhibitors in media
conditioned by tumour cells
Table 2 summarizes the results of the screening of the ECM
proteases and protease inhibitors delivered by the tumour cells to
the culture media carried out in the present work. None of the
activities which were tested could be detected in media condi-
tioned by the low proliferation rate BT-474 and ZR-75-1 breast
cancer cells. We also failed to detect any of the activities in the
medium conditioned by the highly proliferant LAN-5 neuroblas-
toma cells. Therefore, these three cell lines could not be further
used in the study of the potential modulatory effects of genistein
and 2-methoxyestradiol on the proteolytic balances.
The most interesting results were obtained with the media
conditioned by A-204, Hs578T, HT-1080, MDA-MB231, U2-OS
and WAC2 cells, which were further analysed. Only one of the
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Figure 1 Growth profiles for the different human tumour cell lines tested under the culture conditions described in Material and Methodsactivities tested was detected in the media conditioned by HT-29
and MCF-7 (TIMP activity) and SKBR-3 cells (MMP-2 activity).
Since MMP-9 activity was only detected in HT-1080 and
U2-OS cells, we restricted our study to the evaluation of the
MMP-2/TIMP-2 and uPA/PAI proteolytic balances.
Effects of genistein and 2-methoxyestradiol on type IV
collagenase and TIMP activities
Figure 4 summarizes the results obtained with gelatinolytic assays
in both direct and reverse zymograms. As mentioned above,
92 kDa-type IV collagenase (MMP-9) was only detected in the
media conditioned by HT-1080 and U2-OS cells. In reverse zymo-
grams, two bands of TIMP activity were detected but we only
further analysed the most prominent one, that corresponding to
TIMP-2. Table 3 shows the normalized quantitative data obtained
by digital analysis of the gelatinograms. In all the cases tested,
genistein induced a significant decrease in gelatinolytic activities
(greater for MMP-2 activity than for MMP-9 activity).
Furthermore, in HT-1080 and WAC-2 cells a parallel increase in
the size of TIMP-2 activity bands was observed. Both effects
accounted for an important decrease in the MMP-2/TIMP-2 prote-
olytic balance.
The results obtained with 2-methoxyestradiol were less conclu-
sive. In fact, in media conditioned by Hs578T-, HT-1080- or
U2-OS-treated cells, there were simultaneous increases in both
gelatinolytic and TIMP activities with no significant changes in
the proteolytic balance. On the contrary, in media conditioned by
WAC2-treated cells, there were more pronounced increases in the
TIMP activities than those produced in the gelatinolytic activities,
20 I Fajardo et al
British Journal of Cancer (1999) 80(1/2), 17–24 © Cancer Research Campaign 1999
Table 1 Comparison of the antiproliferative effect of genistein and 2-
methoxyestradiol on human tumor cell lines
IC50 (mM)
Tumour line Genistein 2-Methoxyestradiol
BT-474 33 12.0
Hs578T 65 1.0
MCF-7 72 3.0
MDA-MB231 23 0.4
SKBR-3 65 2.7
ZR-75 128 31.0
A-204 25 0.7
HT-1080 100 1.6
HT-29 32 5.5
LAN-5 25 1.0
U-2OS 185 2.3
WAC2 24 0.8
Table 2 Screening for the detection of ECM proteases and protease
inhibitors by zymogramsa
Tumour MMP-9 MMP-2 Stromelysins TIMPs uPA PAIs
line
BT474 – – – – – –
Hs578T – + – + – –
MCF-7 – – – + – –
MDA-
MB231 – – – + +b +c
SKBR-3 – + – – – –
ZR-75 – – – – – –
A-204 – – – + + –
HT-1080 + + – + + –
HT-29 – – – + – –
LAN-5 – – – – – –
WAC2 – + – + + +
U2-OS + + – + – +
aThe activities detected are indicated by + and those undetectable under the
experimental conditions are indicated by –. buPA activity could only be
detected in media conditioned by genistein-treated cells. cPAI activity could
only be detected in media conditioned by 2-methoxyestradiol-treated cells.
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Figure 2 Effects of genistein (G) and 2-methoxyestradiol (M) on the
morphology of cultured human tumour HT-1080 (1), HT-29 (2) and WAC2 (3)
cells, as compared to control cells (C)
Figure 3 Effects of genistein (G) and 2-methoxyestradiol (M) on the
morphology of cultured human tumour MCF-7(1), MDA-MB231 (2) and
SKBR-3 (3) cells, as compared to control cells (C)giving rise to a significant decrease of the proteolytic balance
(Table 3). In media conditioned by 2-methoxyestradiol-treated
SKBR-3 cells, the only activity detected, namely that corre-
sponding to MMP-2, was apparently increased by 25% as
compared to control, untreated cells (results not shown).
Effects of genistein and 2-methoxyestradiol on uPA and
PAI activities
Figure 5 shows typical results obtained in the zymograms carried
out to detect PA and PAI activities, and Table 4 shows the
normalized quantitative data obtained by digital analysis of the
zymograms. As it was the case for the MMP-2/TIMP-2 balance,
genistein strongly modified the uPA/PAI balance to antiproteolysis
in WAC2 cell conditioned media by simultaneous increase of PAI
and decrease of uPA activities. It is noteworthy to remark the
dramatic increase in PAI activity detected in the medium condi-
tioned by genistein-treated WAC2 cells as compared to untreated
cells. In all the cases, genistein produced a pronounced decrease in
uPA and an increase in PAI activity.
On the other hand, 2-methoxyestradiol increased uPA activity in
A-204, HT-1080 and WAC2 cell conditioned media and it
produced no significant effect on the PAI activity detected in
U2-OS conditioned media.
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Table 3 Quantification of MMP-2 and TIMP-2 activities by image analysis
Treatment/cell MMP-2 activitya TIMP-2 activitya MMP-2/TIMP-2b
line
Genistein
Hs578T 0.82 ± 0.07c 1.08 ± 0.20 0.78 ± 0.11c
HT-1080 0.72 ± 0.02c 1.20 ± 0.02c 0.60 ± 0.01c
U2-OS 0.75 ± 0.12d 0.99 ± 0.16 0.75 ± 0.08c
WAC2 0.77 ± 0.01c 1.37 ± 0.10c 0.54 ± 0.00c
2-Methoxyestradiol
Hs578T 1.10 ± 0.10 1.16 ± 0.25 0.97 ± 0.14
HT-1080 0.88 ± 0.25 1.26 ± 0.24 0.71 ± 0.24d
U2-OS 1.21 ± 0.28 1.17 ± 0.17 1.08 ± 0.36
WAC2 1.09 ± 0.03d 1.36 ± 0.04c 0.79 ± 0.01c
aResults are means ± s.d. of three different experiments, except in the case
of WAC2 cells, where they are means of two different experiments. Results
are given as the ratios of activities (treated cells/control cells). Thus, a value
below 1 indicates a decrease and a value over 1 indicates an increase in
activity as compared to control values. bThese are ratios of the values given
in the two previous columns. Here, a value below 1 indicates that the
treatment induced a shift towards antiproteolysis and a value over 1 indicates
that the treatment induced a shift towards an increased proteolysis.
cSignificant versus control values (P<0.01) and dsignificant versus control
values (P<0.05), according to a non-parametric Mann–Whitney’s U-test.
Table 4 Quantification of plasminogen activator and plasminogen activator
inhibitor activities by image analysisa
Treatment/tumour line uPA activity PAI activity
Genistein
A-204 0.30 –
HT-1080 0.52 –
U2-OS – 1.30
WAC2 0.00 12.00
2-Methoxyestradiol
A-204 1.65 –
HT-1080 1.26 –
U2-OS – 0.94
WAC2 2.14 –
aQuantitative data here shown are the results of image analysis of data
shown in Figure 2. They are typical results and they are given as the ratios of
activities (treated cells/control cells). Thus, a value below 1 indicates a
decrease and a value over 1 indicates an increase in activity as compared to
control values. A minus sign indicates that there was no detectable activity in
control cells under the experimental conditions.
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Figure 4 Bands of gelatinolytic activities (MMP-9 and MMP-2) or TIMP-2
activity detected by direct or reverse gelatinograms, respectively, of media
conditioned by human tumour HT-1080 (A), Hs578T (B), U2-OS (C), or
WAC-2 (D). Treatments: control, untreated cells (C), 50 mM genistein (G), or
10 mM 2-methoxyestradiol (M)
Figure 5 Bands of uPA or PAI activities detected by plasminogen
zymography of media conditioned by human tumour WAC2 (A), A-204 (B),
HT-1080 (C), MDA-MB231 (D) or U2-OS (E). Treatments: control, untreated
cells (C), 50 mM genistein (G), or 10 mM 2-methoxyestradiol (M).The case of MDA-MB231 cells is interesting: media condi-
tioned by control, untreated cells contained no detectable uPA or
PAI activities; however, the treatment with 50 mM genistein gave
rise to a detectable band of PAI activity and, on the contrary, the
treatment with 10 mM 2-methoxyestradiol gave rise to a detectable
band of uPA activity.
DISCUSSION
Modulation of tumour cell proliferation
The interest in genistein as a potential anti-cancer agent can be
traced back to the seminal work by Akiyama et al (1987) which
firstly showed that it was a specific and quite potent inhibitor of
protein tyrosine phosphorylation. It has been shown that genistein
inhibits both oestrogen and growth factor stimulated proliferation
of human breast cancer cells (Peterson and Barnes, 1996). This
dual role of genistein is consistent with its previously proposed
role as agonist/antagonist of oestrogen activity (Barnes et al,
1994). In fact, genistein inhibits the growth of both oestrogen-
dependent and oestrogen-independent breast cancer cells, as firstly
reported by Peterson and Barnes (1991). The interest in genistein
as a potential therapeutic agent was reinforced when it was
isolated from human urine and it was shown to inhibit tumour cell
growth in some paediatric tumour cell lines and in some models of
neoplasia in vivo (Schweigerer et al, 1992; Fotsis et al, 1993). Our
results show that both compounds are inhibitory for the growth of
a wide range of tumour cells. In particular, our data confirm that
previously reported by Peterson and Barnes (1991), stating that
genistein can inhibit the proliferation of human breast cancer cells.
At the same time, the cytotoxicity of these compounds was much
lower on non-neoplastic cells (results not shown). The morpho-
logical changes induced by genistein in highly proliferant tumour
cells suggest that this compound could contribute to a reversion of
the tumoural phenotype. Interestingly, it has been shown that
genistein can induce some cancer cells to enter apoptosis
(Gorczyca et al, 1993).
As was the case for genistein, 2-methoxyestradiol was also
isolated from human urine and it was shown to inhibit tumour
cell growth in some paediatric tumour cell lines and in some
models of neoplasia in vivo (Fotsis et al, 1994). We have found
that, in general, 2-methoxyestradiol was more toxic to tumour
cells than genistein. On the other hand, the effect induced by
2-methoxyestradiol on cell morphology reinforces the mechanism
of action suggested by Fotsis et al (1994): as 2-methoxyestradiol-
treated cells lose their shape, it could be speculated that this is the
result of some kind of cytoskeleton disruption. In fact, it has been
shown that 2-methoxyestradiol acts as a ligand for tubulin by
binding to the colchicin site of this cytoskeleton protein, inhibiting
the assembly of the tubulin monomer or the stability of the tubulin
polymer (D’Amato et al, 1994). This interference with the micro-
tubular net could explain the potent anti-tumour effect of
2-methoxyestradiol. Due to the similarity in the actions of both
agents, taxol and 2-methoxyestradiol, it could be suggested that
2-methoxyestradiol could induce apoptosis, as taxol does, and that
this induction occurs in parallel to an activation of p34cdc2
(Donaldson et al, 1994); this suggestion remains to be tested.
Modulation of the proteolytic balance
A second common point of interest of genistein and 2-
methoxyestradiol is their demonstrated capacity to inhibit
angiogenesis (Fotsis et al, 1993, 1994), because of the fact that
solid tumour progression and metastasis are dependent on angio-
genesis (Folkman and Shing, 1992). An essential step in cancer
invasion, angiogenesis and metastasis is a proteolytic degradation
of ECM (Liotta et al, 1991). A positive correlation among tumour
invasiveness and ECM protease levels has been shown (Kohn and
Liotta, 1995). On the other hand, experimental evidences accumu-
late for a negative correlation between TIMP activities and the
metastasic potential of tumour cells (Álvarez et al, 1990; Tsuchiya
et al, 1993). Thus, it seems that there is a direct relationship
between an imbalance of the proteolytic equilibrium towards
proteolysis and the onset of tumour invasion and metastasis. In
fact, Packman et al (1995) have found in thyroid follicular carci-
noma that both uPA and type IV-collagenases are expressed at
higher levels in a more invasive cell line (FTG-238) than in a less
invasive one (FTG-133). Lau et al (1995) have found in colorectal
adenocarcinoma samples higher level of uPA and its receptor than
in their corresponding healthy, control samples. Stearns et al
(1993) have found a positive correlation among MMP2 expression
and malignancy in bladder cancer.
Two main conclusions can be derived from all these findings.
First, the evaluation of the expression levels of ECM proteases
and their inhibitors could have a prognostic value. In fact, it has
been shown that both MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios
are lower in cervix carcinoma with a good prognosis than in
those with a bad prognosis (Nuovo et al, 1995) and that the
MMP-2/TIMP-2 ratio is high in relapsed urothelial cancers (Gohji
et al, 1996). It should be stressed that the changes in the values of
the protease/inhibitor ratios are more significant than the changes
only in the levels of either proteases or inhibitors. Our own results
shown here support this hypothesis and seem to indicate that
zymograms are convenient, easy, rapid, sensitive and economic
procedures to evaluate the proteolytic balance. However, the use
of the proteolytic balance values as prognostic indicators requires
the establishment of acceptable reference patterns as well as the
determination of the cancer types where this method could be
useful.
A second hypothesis is that the modulation of the proteolytic
balance towards antiproteolysis could avoid tumour invasion and
metastasis. In fact, this suggestion is also supported by several
experimental data (Liotta et al, 1991; Montesano, 1992). Thus, the
modulation of the proteolytic balance could be a promising
anti-tumour strategy, and it would be noteworthy to promote the
search for new compounds with a potential capacity to shift the
proteolytic balance towards antiproteolysis.
Genistein has been described as a natural inhibitor of tumour
cell growth (Peterson and Barnes, 1991; Schweigerer et al, 1992).
Afterwards, it has been shown that genistein is an inhibitor of
angiogenesis; in fact, genistein inhibits vascular endothelial cell
proliferation through collagenic matrices as newly formed capilars
(Fotsis et al, 1993). It was postulated that the anti-angiogenic
effect of genistein could be due to its effect on ECM proteases and
their inhibitors. This hypothesis was initially supported by the
reported inhibitory effect of genistein on both uPA and PAI activi-
ties delivered to culture media conditioned by vascular endothelial
cells (Fotsis et al, 1993). Recently, we have shown that genistein
reduces the levels of MMP-2 activity in some paediatric tumour
cell lines (García de Veas et al, 1995). The present report expands
our previous preliminary observations to a wider range of tumours,
and emphasizes the modulatory effect of genistein on the MMP-
2/TIMP-2 and uPA/PAI ratios towards antiproteolysis in different
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result of both inhibition of proteases and activation of protease
inhibitors.
On the other hand, since 2-methoxyestradiol has been described
as an anti-angiogenic compound able to inhibit the induction of
uPA activity by basic fibroblast growth factor in vascular endothe-
lial cells (Fotsis et al, 1994), we postulated that this compound
could modulate the proteolytic balance in a similar way to that
proven for genistein. This was not the case, as demonstrated in the
present work. Our results show that 24 h of treatment with 10 mM
2-methoxyestradiol induces either an apparent increase of uPA
activity or an apparent decrease of PAI activity. The effects of
2-methoxyestradiol on the MMP-2/TIMP-2 ratio seem to be
dependent on the cell line tested. Thus, it seems that the anti-
angiogenic effect of 2-methoxyestradiol is not only due to a modu-
lation of the proteolytic balance. Taking into account the effects of
this compound on cell morphology caused by its capacity to bind
cytoskeleton proteins, we suggest that its anti-angiogenic effect
could be produced by some interferences in the first step of
adhesion to the ECM previous to its degradation; interferences in
the posterior step of migration cannot be ruled out.
CONCLUSION
It seems that this new strategy of searching for efficient and
selective modulators of the proteolytic balance could be very
promising for cancer research; furthermore, these findings would
be relevant for the design and establishment of new therapeutic
strategies against other diseases in which a pathological angiogen-
esis is involved. However, it should be kept in mind that tumour
promotion, invasion and metastasis are very complex phenomena
in which many gene products other than ECM proteases and their
inhibitors are involved. In the present comparative study, we
demonstrate that genistein is an anti-angiogenic compound able to
modulate the proteolytic balance towards antiproteolysis, but the
anti-angiogenic compound 2-methoxyestradiol has no clear anti-
proteolytic effect. Other possibilities remain to be elucidated in
further experimental efforts.
In addition to the potential therapeutic value of genistein, a
dietary-derived tumour cell growth inhibitor, its preventive value
should be stressed. In fact, people in some Asian contries consume
on the average 20–50 times more soy products (rich in genistein)
than in Western countries (Messina et al, 1994), where breast,
prostate and bladder cancer mortalities are higher (Dunn, 1975;
Severson et al, 1989; Parker et al, 1996).
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